Story perspectives

Genentech Signs $1.27B Deal for Alector’s AL050

By Drooid · Oct 5, 2026, 10:21 PM UTC · How we work

Summary

Story summary

Genentech, Roche’s U.S. unit, signed a licensing deal for Alector’s AL050 therapy.
The deal includes $100 million upfront and up to $1.17 billion in milestones, total $1.27 billion.
Genentech obtained exclusive worldwide rights to develop, manufacture and commercialize AL050.
The deal extends Alector’s cash runway to 2029, with $172.8 million cash on hand.
Alector previously lost GSK and AbbVie partnerships after clinical failures, prompting a 49% staff reduction.

1 of 1

Story summary

Genentech, Roche’s U.S. unit, signed a licensing deal for Alector’s AL050 therapy.
The deal includes $100 million upfront and up to $1.17 billion in milestones, total $1.27 billion.
Genentech obtained exclusive worldwide rights to develop, manufacture and commercialize AL050.
The deal extends Alector’s cash runway to 2029, with $172.8 million cash on hand.
Alector previously lost GSK and AbbVie partnerships after clinical failures, prompting a 49% staff reduction.